Gilead Sciences (GILD) Operating Margin Growth (1y) (2010 - 2026)
Gilead Sciences (GILD) Operating Margin Growth (1y) (2010 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Operating Margin Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 654.08 Bn | 633.32 Bn | 17.26 Bn | 22.00 |
| 2 | AbbVie | 470.80 Bn | 464.23 Bn | 12.70 Bn | 613.00 |
| 3 | Merck | 377.96 Bn | 370.82 Bn | 12.21 Bn | -3,510.00 |
| 4 | Novartis Ag | 303.49 Bn | 295.80 Bn | 11.24 Bn | -164.00 |
| 5 | Astrazeneca | 257.97 Bn | 253.07 Bn | 12.86 Bn | -370.00 |
| 6 | Amgen | 236.98 Bn | 222.99 Bn | 7.24 Bn | 602.00 |
| 7 | Gilead Sciences | 182.41 Bn | 179.23 Bn | 6.22 Bn | -16,814.00 |
| 8 | Pfizer | 159.49 Bn | 147.79 Bn | 10.94 Bn | -611.00 |
| 9 | Gsk | 106.28 Bn | 102.11 Bn | 8.24 Bn | -1,961.00 |
| 10 | Sanofi | 55.08 Bn | 47.70 Bn | 10.79 Bn | 170.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -16,814.00 |
| Mar 31, 2026 | 360.00 |
| Dec 31, 2025 | -736.00 |
| Sep 30, 2025 | 3,105.00 |
| Jun 30, 2025 | -309.00 |
| Mar 31, 2025 | 9,820.00 |
| Dec 31, 2024 | 974.00 |
| Sep 30, 2024 | -2,543.00 |
| Jun 30, 2024 | 1,279.00 |
| Mar 31, 2024 | -9,148.00 |
| Dec 31, 2023 | -802.00 |
| Sep 30, 2023 | -309.00 |
| Jun 30, 2023 | -718.00 |
| Mar 31, 2023 | 2,385.00 |
| Dec 31, 2022 | 1,770.00 |
| Sep 30, 2022 | -1,149.00 |
| Jun 30, 2022 | -371.00 |
| Mar 31, 2022 | -4,201.00 |
| Dec 31, 2021 | -2,275.00 |
| Sep 30, 2021 | 2,135.00 |